

# Reimbursement and payment of health apps: Industry Perspective

**Panos Kokkinos, Value and Innovation-based Access Officer,  
MedTech Europe**


# MedTech Europe

The European trade association for the medical technology industry including diagnostics, medical devices and digital health.

## OUR MEMBERS



145+ multinational corporations\*



50 medical technology associations



## PURPOSE

MedTech Europe's purpose is to make innovative medical technologies available to more people, while helping healthcare systems move towards a more sustainable path


# Challenges in the Reimbursement and Payment of Health Apps



POSITION PAPER



# What do we mean by payment



# Funding Mechanisms

## Public sector

**Innovative Payment Schemes (IPS):** Agreements that provide temporary coverage and/or funding to enable patient access to medical technologies and procedures outside general reimbursement and funding frameworks


**Dedicated pathways for reimbursement of apps:** Clear and adequate funding and reimbursement frameworks to incentivise the adoption of digital health solutions which have demonstrated benefits for patients or the healthcare system.

## Private sector

- Private financing with private insurers
- Person perspective with co-payment

# European countries with active innovative payment schemes

- 32** countries were screened
- 21** innovative payment schemes
- 8** countries have established innovative payment schemes: Austria, Belgium, England, France, Germany, the Netherlands, Spain, and Switzerland
- 18** coverage with evidence development (CED) schemes
- 3** unconditional innovation payment schemes



Notes: (1) Unconditional innovation payment schemes: scheme for which there is no requirement to produce additional evidence at the exit of the scheme. (2) CED schemes: schemes when reimbursement/funding is granted to promising technologies with some evidence gaps, which can be bridged during a limited timeframe of temporary coverage. (3) unconditional innovation payment schemes were previously called unconditional innovative funding schemes (4) A reimbursement model for digital technologies in France and a program in Scotland are in development

# European countries actively transform their healthcare systems and/or the reimbursement and funding systems


**32** countries were screened

**33** ongoing initiatives to transform health care systems

**17** countries and regions


**9** major trends

- New procedural classifications
- New hospital DRG systems
- New innovative payment schemes
- New HTA programs
- Programs in genomic medicine
- New out-patient payment systems
- Change of administrative landscape
- Programs in digital health
- Prioritisation methods for technologies




For the counting of number of countries, England and Scotland were counted as one country (the UK)

# Digital Transformation and Reimbursement for Digital Health





# Cost Effects



Increased cost of care

Investment effect

- Full care pathway
- Reducing the total cost of care
- Societal costs

# Existing Budgets

*Value Framework in the area of purchasing and procurement*




Label as an entry point



Label as awarding element

# Investors Interest



- ✓ ROI → Link to reimbursement and funding
- ✓ Early Value Assessment
- ✓ Value-based approach for assessment
- ✓ Innovative Payment Schemes
- ✓ Dedicated schemes to improve the efficiencies of regulatory processes (Notified Body Capacity Building)

# Thank You!

**Panos Kokkinos**

[p.kokkinos@medtecheurope.org](mailto:p.kokkinos@medtecheurope.org)

[www.medtecheurope.org](http://www.medtecheurope.org)